199 related articles for article (PubMed ID: 9697781)
1. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.
Andriole GL; Guess HA; Epstein JI; Wise H; Kadmon D; Crawford ED; Hudson P; Jackson CL; Romas NA; Patterson L; Cook TJ; Waldstreicher J
Urology; 1998 Aug; 52(2):195-201; discussion 201-2. PubMed ID: 9697781
[TBL] [Abstract][Full Text] [Related]
2. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.
Roehrborn CG; Boyle P; Bergner D; Gray T; Gittelman M; Shown T; Melman A; Bracken RB; deVere White R; Taylor A; Wang D; Waldstreicher J
Urology; 1999 Oct; 54(4):662-9. PubMed ID: 10510925
[TBL] [Abstract][Full Text] [Related]
3. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.
Bruskewitz R; Girman CJ; Fowler J; Rigby OF; Sullivan M; Bracken RB; Fusilier HA; Kozlowski D; Kantor SD; Johnson EL; Wang DZ; Waldstreicher J
Urology; 1999 Oct; 54(4):670-8. PubMed ID: 10510926
[TBL] [Abstract][Full Text] [Related]
4. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group.
Oesterling JE; Roy J; Agha A; Shown T; Krarup T; Johansen T; Lagerkvist M; Gormley G; Bach M; Waldstreicher J
Urology; 1997 Jul; 50(1):13-8. PubMed ID: 9218012
[TBL] [Abstract][Full Text] [Related]
5. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
[TBL] [Abstract][Full Text] [Related]
6. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
[TBL] [Abstract][Full Text] [Related]
7. [Effect of finasteride on the percentage of free PSA: implications in the early diagnosis of prostatic cancer].
Morote J; Lorente JA; Raventós CX; López MA; Encabo G; De Torres I; López M; De Torres JA
Actas Urol Esp; 1998; 22(10):835-9. PubMed ID: 9949572
[TBL] [Abstract][Full Text] [Related]
8. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.
Pannek J; Marks LS; Pearson JD; Rittenhouse HG; Chan DW; Shery ED; Gormley GJ; Subong EN; Kelley CA; Stoner E; Partin AW
J Urol; 1998 Feb; 159(2):449-53. PubMed ID: 9649261
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification.
Ankerst DP; Thompson IM
Arch Ital Urol Androl; 2006 Dec; 78(4):125-9. PubMed ID: 17269614
[TBL] [Abstract][Full Text] [Related]
10. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.
Yang XJ; Lecksell K; Short K; Gottesman J; Peterson L; Bannow J; Schellhammer PF; Fitch WP; Hodge GB; Parra R; Rouse S; Waldstreicher J; Epstein JI
Urology; 1999 Apr; 53(4):696-700. PubMed ID: 10197843
[TBL] [Abstract][Full Text] [Related]
11. Effect of finasteride on prostate-specific antigen density.
Gormley GJ; Ng J; Cook T; Stoner E; Guess H; Walsh P
Urology; 1994 Jan; 43(1):53-8; discussion 58-9. PubMed ID: 7506854
[TBL] [Abstract][Full Text] [Related]
12. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group.
Oesterling JE; Roy J; Agha A; Shown T; Krarup T; Johansen T; Lagerkvist M; Gormley G; Bach M; Waldstreicher J
Urology; 1998 Apr; 51(4A Suppl):58-63. PubMed ID: 9586598
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
15. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study.
Albertsen PC; Pellissier JM; Lowe FC; Girman CJ; Roehrborn CG
Clin Ther; 1999 Jun; 21(6):1006-24. PubMed ID: 10440624
[TBL] [Abstract][Full Text] [Related]
16. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group.
Kaplan S; Garvin D; Gilhooly P; Koppel M; Labasky R; Milsten R; Reddy P; Rosenberg S; Sussman D; White C; Lee M; Pappas F; Waldstreicher J
Urology; 2000 Oct; 56(4):610-6. PubMed ID: 11018616
[TBL] [Abstract][Full Text] [Related]
17. The effect of finasteride on prostate specific antigen: review of available data.
Guess HA; Gormley GJ; Stoner E; Oesterling JE
J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
[TBL] [Abstract][Full Text] [Related]
18. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial.
Walsh PC
J Urol; 1999 Jan; 161(1):350-1. PubMed ID: 10037436
[No Abstract] [Full Text] [Related]
19. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
Andriole GL; Marberger M; Roehrborn CG
J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
[TBL] [Abstract][Full Text] [Related]
20. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.
Wessells H; Roy J; Bannow J; Grayhack J; Matsumoto AM; Tenover L; Herlihy R; Fitch W; Labasky R; Auerbach S; Parra R; Rajfer J; Culbertson J; Lee M; Bach MA; Waldstreicher J;
Urology; 2003 Mar; 61(3):579-84. PubMed ID: 12639651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]